2 weeks Ago By ABMN Staff
Clearline Capital LP lowered its stake in shares of Nautilus Biotechnology, Inc. ( NASDAQ:NAUT – Free Report ) by 2.9% in the second quarter, according to its most recent 13F filing with the SEC.
The fund owned 164,073 shares of the company’s stock after selling 4,911 shares during the period. Clearline Capital LP’s holdings in Nautilus Biotechnology were worth $384,000 at the end of the most recent quarter. Several other institutional investors and hedge funds have also modified their holdings of NAUT.
Price T Rowe Associates Inc. MD raised its position in Nautilus Biotechnology by 35.8% during the first quarter.
Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after acquiring an additional 4,239 shares in the last quarter. China Universal Asset Management Co.
Ltd. boosted its position in Nautilus Biotechnology by 66.6% in the 1st quarter.
China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock worth $71,000 after purchasing an additional 9,624 shares in the last quarter.
Renaissance Technologies LLC grew its stake in shares of Nautilus Biotechnology by 11.2% during the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after purchasing an additional 14,100 shares during the period.
Dimensional Fund Advisors LP increased its holdings in shares of Nautilus Biotechnology by 19.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after purchasing an additional 94,908 shares in the last quarter.
Finally, Clarius Group LLC lifted its stake in shares of Nautilus Biotechnology by 2.7% in the 2nd quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock valued at $1,489,000 after purchasing an additional 16,661 shares during the period.
Institutional investors and hedge funds own 50.71% of the company’s stock. Analyst Upgrades and Downgrades Several analysts recently commented on the stock.
Jefferies Financial Group began coverage on shares of Nautilus Biotechnology in a research report on Monday, June 3rd. They set a “hold” rating and a $3.00 price target on the stock.
Guggenheim began coverage on Nautilus Biotechnology in a research note on Thursday, June 27th. They issued a “buy” rating and a $6.00 price target for the company.
Insider Buying and Selling In related news, VP Mary E. Godwin sold 47,031 shares of Nautilus Biotechnology stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $2.
87, for a total value of $134,978.97. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink .
Insiders own 40.50% of the company’s stock. Nautilus Biotechnology Price Performance Shares of NAUT stock opened at $2.
91 on Friday. Nautilus Biotechnology, Inc. has a 1-year low of $2.
19 and a 1-year high of $3.45. The company has a market cap of $364.
94 million, a price-to-earnings ratio of -5.29 and a beta of 1.20.
The stock has a 50 day simple moving average of $2.62 and a 200-day simple moving average of $2.60.
Nautilus Biotechnology ( NASDAQ:NAUT – Get Free Report ) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.
16) by $0.02. During the same quarter last year, the firm earned ($0.
13) EPS. Analysts anticipate that Nautilus Biotechnology, Inc. will post -0.
65 earnings per share for the current fiscal year. About Nautilus Biotechnology ( Free Report ) Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
See Also Want to see what other hedge funds are holding NAUT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nautilus Biotechnology, Inc. ( NASDAQ:NAUT – Free Report ).
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter ..
